NKTX logo

NKARTA INC

NKTXNASDAQ
πŸ† #3958 by market capEarnings Mar 24US Equity
$1.14β–² $0.02 (+1.34%)
Market closed Β· at close
πŸ””
Track NKTX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.3%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$81M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
52
Fair
No chart data available for NKTX.

Trading Snapshot

Day Range
$1.11 – $1.22
52-Week Range
$1.11 – $3.72
Volume (shares)
1,603,457
Avg Volume (shares)
β€”
Shares Outstanding
71.6M
Next Earnings
2027-03-24

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-0.7
P/S Ratio
0.0x
EPS (TTM)
$-1.73
Dividend Yield
0.00%
Dilution (1yr)
+0.6%
NKTX logo

NKARTA INC

NKTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$121Mβ–Ό βˆ’5.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$90Mβ–Ό βˆ’13.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
74.0Mβ–² +0.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$37Mβ–² +$16M YoY
StockOtter Β· stockotter.space

About NKARTA INC

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
52/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·11d ago

Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026

No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or graft-versus-host

Seeking AlphaΒ·13d ago

Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis Transcript

Nkarta, Inc. ( NKTX ) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis November 9, 2026 8:00 AM EST Company Participants Paul Hastings - CEO & Director Shawn Rose - Chief Medical Officer and Head

GlobeNewsWireΒ·13d ago

Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence

In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in the Ntrust-2 study of

GlobeNewsWireΒ·16d ago

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, to

GlobeNewsWireΒ·17d ago

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, to

Defense WorldΒ·Sep 28

Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance

Nkarta (NASDAQ: NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including presentations in myosi